Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain
The Oncologist · 08.07.2026 · 31 (8)
DOI: 10.1093/oncolo/oyag163 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Oncologist, online erschienen am 16.07.2026. Verfasst von Jennifer Segar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Next Oncology, Houston, TX, United States. Hauptthemen laut MEDLINE: Analgesics, Opioid, Bone Neoplasms, Breast Neoplasms, Cancer Pain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, Comprehensive Pain and Addiction Center (CPAC), University of Arizona Health Sciences, University of Arizona Cancer Center.
Abstract (Originalsprache)
Background
Bone metastases (BM) from breast cancer cause significant cancer-induced bone pain (CIBP). Management of CIBP is primarily with opioids, which have notable side effects. In preclinical models, cannabinoid receptor (CB)2 and CB1 agonists were shown to decrease CIBP and bone degradation. We hypothesized that the addition of CB2/CB1 agonists would decrease opioid requirements in patients with BM.
Methods
We conducted a single-arm study among breast cancer patients with BM on opioid therapy. Patients were treated with 10 mg dronabinol BID for 8 weeks. Our primary objective was to determine the proportion who decreased their opioid use by ≥ 20%. Participants completed the Brief Pain Inventory and the European Organization for Research and Treatment of Cancer quality of life questionnaires before and after treatment. Pre- and post-treatment blood and urine were collected for analysis of biomarkers of bone remodeling.
Results
We enrolled 14 evaluable patients, and 4 decreased opioid use by ≥ 20%, meeting the primary endpoint. Patients reported significant improvements in pain severity, interference scores, quality of life, and insomnia. There was one grade 3 adverse event (dizziness) related to the study drug. A significant decrease was noted in serum C-terminal telopeptide levels with therapy.
Conclusion
Our pilot study shows that the addition of dronabinol resulted in decreased opioid requirements for CIBP. Patient-reported outcomes also demonstrated improved pain and QOL with addition of dronabinol. Our results are promising and warrant further investigation into novel analgesics for CIBP to decrease opioid use. ClinicalTrials.gov NCT03661892
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Next Oncology, Houston, TX, United States.
- Department of Psychiatry, University of Arizona, Tucson, AZ, United States.
- Department of Surgery, University of Wisconsin, Madison, WI, United States.
- Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, United States.
- Department of Biostatistics, University of Arizona Cancer Center, Tucson, AZ, United States.
- Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, United States.
ORCID-Profile: Mary Junak, Pavani Chalasani
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- Comprehensive Pain and Addiction Center (CPAC), University of Arizona Health Sciences, University of Arizona Cancer Center
Zitieren
APA
Segar, J., Farr, K., Junak, M., Roe, D., Ehsani, S., Ibrahim, M., Vanderah, T. W., & Chalasani, P. (2026). Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag163
Vancouver
Segar J, Farr K, Junak M, Roe D, Ehsani S, Ibrahim M, et al. Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag163
BibTeX
@article{Segar2026,
author = {Segar, Jennifer and Farr, Kiah and Junak, Mary and Roe, Denise and Ehsani, Sima and Ibrahim, Mohab and Vanderah, Todd W and Chalasani, Pavani},
title = {Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {8},
doi = {10.1093/oncolo/oyag163}
}
EUVIMED